Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25155872 | 1.00 | MC4R (0.49) | MC4RSRCRAB9ASSTR4MAPK1 | |
| SCHEMBL25156474 | 0.81 | HTR2C (0.58) | MC4RSRCRAB9AMAPK1POLB | |
| SCHEMBL25156178 | 0.81 | ALDH1A1 (0.56) | SRCPOLBCHRM3HTR2CHTR2B | |
| SCHEMBL29583269 | 0.81 | ALDH1A1 (0.56) | SRCPOLBCHRM3HTR2CHTR2B | |
| SCHEMBL25155624 | 0.78 | SRC (0.53) | SRCRAB9AMAPK1POLBCHRM3 | |
| SCHEMBL31359854 | 0.78 | SRC (0.53) | SRCRAB9AMAPK1POLBCHRM3 | |
| SCHEMBL5392713 | 0.77 | ALDH1A1 (0.68) | SRCPOLBALDH1A1HPGDTHRB | |
| SCHEMBL31359953 | 0.75 | GPR119 (0.52) | SSTR4MCHR1ALDH1A1THRB | |
| SCHEMBL25155871 | 0.75 | GPR119 (0.52) | SSTR4MCHR1ALDH1A1THRB | |
| SCHEMBL30344314 | 0.75 | GPR119 (0.52) | SSTR4MCHR1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | MC4R 4333/4885SRC 2595/4885RAB9A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.